Anal Chem by Phinney, Karen W. et al.
Development of a Standard Reference Material for Metabolomics 
Research
Karen W. Phinney*,⊥, Guillaume Ballihaut#, Mary Bedner#, Brandi S. Benford#, Johanna E. 
Camara#, Steven J. Christopher#, W. Clay Davis#, Nathan G. Dodder#,†, Gauthier Eppe#,‡, Brian 
E. Lang□, Stephen E. Long#, Mark S. Lowenthal⊥, Elizabeth A. McGaw#,§, Karen E. Murphy#, 
Bryant C. Nelson□, Jocelyn L. Prendergast#,‖, Jessica L. Reiner#, Catherine A. Rimmer#, Lane C. 
Sander#, Michele M. Schantz#, Katherine E. Sharpless#, Lorna T. Sniegoski#, Susan S.-C. Tai#, 
Jeanice B. Thomas#, Thomas W. Vetter#, Michael J. Welch#, Stephen A. Wise#, Laura J. Wood#, 
William F. Guthrie$, Charles R. Hagwood$, Stefan D. Leigh$, James H. Yen$, Nien-Fan Zhang$, 
Madhu Chaudhary-Webb%, Huiping Chen%, Zia Fazili%, Donna J. LaVoie%, Leslie F. McCoy%, 
Shahzad S. Momin%, Neelima Paladugula%, Elizabeth C. Pendergrast%, Christine M. Pfeiffer%, 
Carissa D. Powers%, Daniel Rabinowitz%, Michael E. Rybak%, Rosemary L. Schleicher%, 
Bridgette M. H. Toombs%, Mary Xu%, Mindy Zhang%, and Arthur L. Castleˆ
⊥Biomolecular Measurement Division, National Institute of Standards and Technology, 
Gaithersburg, Maryland 20899, United States
#Chemical Sciences Division, National Institute of Standards and Technology, Gaithersburg, 
Maryland 20899, United States
□Biosystems and Biomaterials Division, National Institute of Standards and Technology, 
Gaithersburg, Maryland 20899, United States
$Statistical Engineering Division, National Institute of Standards and Technology, Gaithersburg, 
Maryland 20899, United States
%Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease 
Control and Prevention, Atlanta, Georgia 30341, United States
ˆNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 
Bethesda, Maryland 20892, United States
*Corresponding Author: Phone: 301-975-4457. karen.phinney@nist.gov.
†Present Addresses: N.G.D.: Southern California Coastal Water Research Project Authority, Costa Mesa, CA 92626.
‡Present Addresses: G.E.: Department of Chemistry, University of Liège, Belgium.
§Present Addresses: E.A.M.: Chemistry Department, Adrian College, Adrian, MI 49221.
‖Present Addresses: J.L.P.: George Mason University, Fairfax, VA 22030.
Supporting Information
Additional information as noted in the text. This material is available free of charge via the Internet at http://pubs.acs.org.
Notes
Certain commercial equipment, instruments, or materials are identified in this paper to specify adequately the experimental procedure. 
Such identification does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it 
imply that the materials or equipment identified are necessarily the best available for the purpose. The findings and conclusions in this 
report are those of the authors and do not necessarily represent the official views or positions of the Centers for Disease Control and 
Prevention/Agency for Toxic Substances and Disease Registry or the Department of Health and Human Services.
The authors declare no competing financial interest.
HHS Public Access
Author manuscript
Anal Chem. Author manuscript; available in PMC 2016 April 06.
Published in final edited form as:














The National Institute of Standards and Technology (NIST), in collaboration with the National 
Institutes of Health (NIH), has developed a Standard Reference Material (SRM) to support 
technology development in metabolomics research. SRM 1950 Metabolites in Human Plasma is 
intended to have metabolite concentrations that are representative of those found in adult human 
plasma. The plasma used in the preparation of SRM 1950 was collected from both male and 
female donors, and donor ethnicity targets were selected based upon the ethnic makeup of the U.S. 
population. Metabolomics research is diverse in terms of both instrumentation and scientific goals. 
This SRM was designed to apply broadly to the field, not toward specific applications. Therefore, 
concentrations of approximately 100 analytes, including amino acids, fatty acids, trace elements, 
vitamins, hormones, selenoproteins, clinical markers, and perfluorinated compounds (PFCs), were 
determined. Value assignment measurements were performed by NIST and the Centers for Disease 
Control and Prevention (CDC). SRM 1950 is the first reference material developed specifically for 
metabolomics research.
Graphical abstract
Metabolites are well-established indicators of human health, and measurement of specific 
metabolites has historically played a key role in disease diagnosis and risk assessment.1 
Fasting blood glucose levels are used to diagnose diabetes,2,3 and serum creatinine levels are 
monitored in assessment of kidney function.4,5 Individual metabolite markers tend to lack 
disease specificity, however, and results outside the normal range may only point to the need 
for further investigation rather than reflecting a clear cause and effect relationship.6,7 For 
example, elevated cholesterol levels are associated with a number of disorders, including 
hypothyroidism, diabetes, and kidney dysfunction. Diseases such as diabetes8 and 
Parkinson’s disease9,10 tend to affect multiple biochemical processes in the body, and 
measurement of a single biomarker is often insufficient for definitive diagnosis or for 
classification of patients into disease subtypes. Therefore, focusing on one or even a few 
metabolites at a time has limited diagnostic or prognostic value and provides little insight 
into disease etiology.11,12
Advances in technology have now made global profiling of hundreds or thousands of 
metabolites present in a given biological sample possible and thus have paved the way for 
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holistic investigations of biochemical pathways and the relationships between them.13,14 An 
examination of the complete collection of metabolites, known as the metabolome,15−17 may 
provide insight into disease mechanisms and identify markers that can pinpoint the early 
stages of disease when interventions are more likely to be effective.6,18 Similarly, 
metabolomics studies are also being employed to understand the mechanisms of drug-
induced toxicity in the hopes of improving drug safety and efficacy.19−22
Metabolomics studies can be either qualitative or quantitative in nature and either targeted 
(hypothesis-driven) or untargeted (global) in design.23,24 Given the complexity of the 
metabolome and the range of metabolite concentrations and polarities routinely encountered, 
no single analytical technique is able to provide a complete picture of the metabolites 
present in a specific sample. Hence, the metabolites observed are dependent to a certain 
extent upon the technique used as well as variables such as sampling and sample preparation 
protocols.25−27 Nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry 
(MS) are the predominant analytical approaches in metabolomics research,14 although there 
have been applications of infrared and Raman spectroscopy as well as other 
techniques.6,15,26 The strengths and limitations of NMR and MS approaches for 
metabolomics have been summarized in a number of reviews.28−31
Regardless of the analytical platform selected, metabolomics research relies upon the ability 
to compare two or more data sets and to identify particular patterns or features that differ 
between them. To achieve this goal and make meaningful comparisons of data, it must be 
possible to isolate “real” differences between samples and data sets from those that arise 
from analytical variability or experimental artifacts.32,33 Thus, identifying and controlling 
sources of intra- and interlaboratory variability have become crucial elements of 
metabolomics research.34,35
Quality control (QC) materials are increasingly being employed in metabolomics as a means 
of assessing data quality and for identifying experimental artifacts.34,36 One approach to the 
implementation of QC materials involves combining aliquots from each of the study samples 
to prepare a QC pool that can be analyzed at the same time as the samples.37 This technique 
can be particularly valuable for studies where samples are analyzed in different batches or if 
changes in instrument performance are suspected.36 However, pooling of sample aliquots 
may not be feasible for long-term studies.38 In addition, further confidence in data quality 
can be gained through the use of standards or QC materials that are independent of the 
samples being analyzed.
Standard Reference Material (SRM) 1950 Metabolites in Human Plasma was developed in 
collaboration with the National Institutes of Health (NIH) in response to a recognized need 
for a reference material to support metabolomics technology development. SRM 1950 
consists of a human plasma pool collected from healthy adults. Concentrations of 
approximately 100 analytes have been determined in this material, including both 
metabolites and environmental contaminants. Isotope-dilution mass spectrometry 
approaches to analyte quantification were used whenever possible. This SRM is the first 
reference material developed specifically for metabolomics research.
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SRM 1950 Metabolites in Human Plasma was prepared by Bioreclamation, Inc. (Hicksville, 
NY) according to specifications provided by NIST. The plasma pool was collected from 100 
donors, with an equal number of men and women and from donors between 40 and 50 years 
of age. Donors were selected to be representative of the ethnic distribution of the U.S. 
population, based upon data from the U.S. Census in 2000. Donors were asked to fast 
overnight and to abstain from taking medications for 72 h prior to blood donation. A rapid 
glucose test was used to exclude individuals who did not comply with the fasting 
requirement. Individuals affected by overt disease or disorders and those having a body mass 
index (BMI) outside the 95th percentile were excluded.
Plasma was prepared from whole blood that was placed on ice immediately after collection, 
and lithium heparin was used as the anticoagulant. Each sample was centrifuged at 4 °C at 
8000 × g for 25 min. Samples were processed and frozen within 60 min from the time of 
collection. Units of plasma were thawed once and blended under nitrogen. The resulting 
plasma pool was dispensed in 1 mL aliquots into vials, and the vials were then stored at 
−80 °C prior to shipment to NIST. Approximately 20 000 vials of SRM 1950 were delivered 
to NIST, and a unit of SRM 1950 consists of 5 vials.
Safety Considerations
Each unit of human plasma used in the preparation of SRM 1950 was screened by 
Bioreclamation and found to be nonreactive for hepatitis B surface antigen (HBsAg), human 
immunodeficiency virus (HIV), hepatitis C virus (HCV), and human immunodeficiency 
virus 1 antigen (HIV-1Ag) by Food and Drug Administration (FDA)-licensed tests. 
However, because no test method can guarantee that these infectious agents are absent, 
appropriate safety precautions should be taken when handling this or any other potentially 
infectious human plasma or blood specimens.39
Methods
Brief descriptions of the methods used in the value assignment of SRM 1950 are provided in 
the Certificate of Analysis40 and are also included in the Supporting Information. Method 
details are also available online (http://srm1950.nist.gov). Some of the methods developed as 
part of the certification of SRM 1950 have been described in related publications.41−43 
Certification measurements were performed at NIST and at the Centers for Disease Control 
and Prevention (CDC, Atlanta, GA). The methods used at NIST had, in most cases, been 
used previously for value assignment of other SRMs. The methods used by CDC had 
previously been validated for use in the National Health and Nutrition Examination Survey 
(NHANES). Analyte quantification was based upon isotope-dilution mass spectrometry (ID-
MS) whenever possible. For analytes such as the carotenoids where ID-MS methods were 
not available, liquid chromatographic methods with UV/visible detection (LC-UV) or 
fluorescence detection (LC-FL) were employed at NIST and CDC. For some of the fatty 
acids and carotenoids, value assignment measurements were performed using a single 
method at the CDC.
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Validation of metabolites or profiles of metabolites as biomarkers will require the 
comparison of data sets from different laboratories and from different analytical platforms. 
Such comparisons are difficult at present, even if adequate experimental details (metadata) 
are provided with the results.1,22,44 The impact of certain preanalytical variables such as 
sample collection and storage can be minimized through the implementation of standard 
operating procedures (SOPs), but it is very difficult to adopt uniform approaches to reduce 
the many potential sources of variability in metabolomics, particularly when complex 
sample preparation and analysis schemes are required.32−34 As a result, experimental 
artifacts may be difficult to identify in the absence of appropriate measurement quality 
assurance materials.
Traditional approaches to detecting and minimizing analytical variability and ensuring 
measurement accuracy may not be easily adapted to metabolomics investigations. Internal 
standards, including stable isotope-labeled internal standards, can aid in correcting for 
variations in factors such as sample preparation, chromatographic retention, and ionization 
efficiency.25 However, in metabolomics studies, selection of appropriate internal standards is 
complicated by the fact that the compounds of interest generally are not known in 
advance.36 In addition, even when the target analytes are known, adding an internal standard 
for each compound when hundreds of analytes are being detected is not a viable option.
Reference materials are another mechanism for validating analytical methods and evaluating 
data quality. NIST SRMs have typically been developed with a particular application in 
mind. For example, SRM 967a Creatinine in Frozen Human Serum is directed toward 
laboratories performing measurements of creatinine in serum. Because metabolomics studies 
encompass such a wide range of interests including toxicology, nutrition, and drug 
development, as well as a number of different analytical platforms, it is nearly impossible to 
match the sample matrixes and metabolite profiles encountered by each end user of a 
potential reference material. An alternative approach is to develop a reference material that 
is as broadly applicable as possible. NIH and a panel of metabolomics investigators provided 
guidance to NIST in designing SRM 1950 Metabolites in Human Plasma and in selecting 
target analytes for value assignment.
SRM 1950 Metabolites in Human Plasma is intended to represent normal human plasma. 
The specifications for the preparation of the plasma pool were designed to minimize the 
influence of factors such as diet and medications on the metabolite profile.45 As noted 
earlier, one of the goals of this work was to develop a reference material that would be 
suitable for applications that were difficult to predict in advance. Therefore, concentrations 
of a broad spectrum of metabolites were determined in SRM 1950, including amino acids, 
carotenoids, fatty acids, electrolytes, hormones, and vitamins. Additional measurements 
were performed for total protein, selenoproteins, and perfluorinated compounds (PFCs). 
PFCs are persistent environmental contaminants, and their concentrations in serum or 
plasma may be of interest for biomonitoring studies. Values were assigned for nearly 100 
different species in SRM 1950, and this information is provided to users of the SRM in a 
Certificate of Analysis.40 The assigned values are presented in the certificate as certified, 
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reference, or information values.46 Both certified and reference values are given with their 
associated uncertainties, which were calculated in accordance with the International 
Organization for Standardization (ISO) Guide.47
The methods used in the certification of SRM 1950 are not intended to be representative of 
analytical approaches typically used in metabolomics research. Candidate analytes of 
interest for value assignment in SRM 1950 were either known in advance or identified 
through preliminary screening of the material, and therefore method selection could be 
optimized. In many cases, metabolite concentrations were determined using methods 
previously employed at NIST for value assignment of other SRMs. These methods generally 
quantify only one or a small group of analytes at a time and are often based upon ID-MS 
approaches to analyte quantification. The following sections describe the value assignment 
process for several classes of metabolites in this reference material. Additional details can 
also be found in the Supporting Information.
Clinical Markers
Traditional clinical markers such as glucose, cholesterol, and triglycerides can be useful as 
surrogate markers for classifying or stratifying samples in metabolomics research.48,49 
Glucose is one of the most abundant metabolites in serum or plasma, and glucose 
metabolism is also known to be altered in a number of disease states, including diabetes.8 
Although electrolytes (calcium, magnesium, potassium, sodium) are not generally 
considered in metabolomics investigations, electrolyte imbalances are associated with a 
number of diseases. They are also some of the more abundant species in human serum or 
plasma.16 Steroid hormone profiles have been studied in relation to endocrine disorders and 
as potential cancer biomarkers.7
Table 1 summarizes the concentrations of the majority of the clinical markers that were 
value assigned in SRM 1950. For some analytes, mass concentrations presented in the table 
were calculated from mass fractions using the measured density of SRM 1950 (1.02086 g/
mL). In general, each of these analytes was determined at NIST by a single method, as 
indicated in the table. Many of these methods are recognized as reference measurement 
procedures by the Joint Committee for Traceability in Laboratory Medicine (JCTLM). The 
GC-MS procedures for the clinical analytes involved derivatization of the analyte of interest 
after isolation from the plasma matrix. Labeled internal standards were added at the 
beginning of the sample preparation process and allowed to equilibrate with the sample for a 
predetermined period of time. A similar approach was utilized for the LC-MS and LC-
MS/MS analyses, but derivatization was not required in these methods. Samples for ICP-MS 
analysis were subjected to acid digestion, and an appropriate isotope spike was employed for 
quantification. For the GC-MS, LC-MS, and LC-MS/MS analyses, the relative expanded 
uncertainties associated with these measurements are generally in the range of 1−3%, and 
relative expanded uncertainties <1% are common for the ICP-MS methods. This method 
performance is reflected in the expanded uncertainties shown with each certified or 
reference value in Table 1.
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Amino acids are the building blocks of proteins and also serve as important metabolic 
intermediates. Measurement of amino acids in biological fluids is routinely used in the 
diagnosis of metabolic disorders.50 Thus, it is not surprising that metabolomics studies have 
frequently detected perturbations in amino acid concentrations that appear to be linked with 
particular disease states.51−53 Research has also indicated that amino acid metabolism is 
altered in diabetes, and certain branched chain amino acids may have utility as early 
indicators of diabetes risk.8,54 In some cases, changes in specific amino acid concentrations 
appear to have merit in classifying patients by disease subtype, as was reported for chronic 
obstructive pulmonary disease (COPD).55
Amino acids were determined in SRM 1950 through a combination of data from four 
independent methods based upon liquid chromatography−tandem mass spectrometry (LC-
MS/MS), gas chromatography−time-of-flight mass spectrometry (GC-TOF-MS), and two-
dimensional GC coupled to time-of-flight mass spectrometry (GCxGC-TOF-MS).41 For the 
GC-TOF-MS analyses, either propyl chloroformate (PCF) or N-methyl-N-(tert-
butyldimethylsilyl)-trifluoroacetamide (MTBSTFA) was used as the derivatizing agent. Only 
MTBSTFA was used as the derivatizing agent for the GCxGC-TOF-MS measurements. 
Isotopically labeled internal standards were employed for each of the amino acids and were 
added at the beginning of the sample analysis. In general, good agreement was observed 
among the results from the four methods. Details on the results from the individual methods 
are presented elsewhere.41 Coefficients of variation (CVs) for the LC-MS/MS method were 
typically in the range of 1−3%, reflecting the excellent precision commonly associated with 
ID-MS methods. The observed CVs for the GC-TOF-MS and GCxGC-TOF-MS analyses 
were generally higher (≈5−10%), perhaps because of the additional sample preparation 
steps that were required for these methods.
The concentrations of 18 amino acids were assigned based upon a combination of the GC-
MS and LC-MS/MS methods, and the certified and reference values are summarized in 
Table 2. Arginine and ornithine could not be determined in SRM 1950 by the GC-MS 
methods because of thermal instability of the arginine derivative, leading to potential 
conversion to ornithine. Histidine could not be determined by GC-TOF-MS because of a 
large interference from glucose, but adding a second dimension to the separation (GCxGC) 
removed the interference. Hence, employing multiple independent methods reduced the 
likelihood of undetected measurement bias and provided greater confidence in the value 
assignment of amino acids in SRM 1950. The results obtained in this work were also 
comparable to a related literature report on analysis of SRM 1950 by NMR56 and to 
information on amino acid concentrations found in the Human Metabolome Database.17 
SRM 1950 is the first serum or plasma-based NIST SRM with values assigned for amino 
acids.
Fatty Acids
Dysregulation of fatty acid metabolism has been implicated in a number of diseases, 
including diabetes8 and cancer.52 Some drug therapies have been shown to cause widespread 
changes in lipid profiles,57 and differences in fatty acid concentrations have also been 
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observed between groups having disparate levels of physical fitness.58 Fatty acids were 
value assigned in SRM 1950 through a combination of GC methods with either flame 
ionization (FID) or mass spectrometric detection. A total of 26 fatty acids were determined 
in SRM 1950, including saturated, monounsaturated, and polyunsaturated fatty acids. The 
results are summarized in Table 3. Of these fatty acids, 14 were measured by a single 
method, either at NIST or at CDC. The two NIST methods (GC-FID and GC-MS) employed 
different sample preparation schemes and different chromatographic columns. The CDC 
method (GC-MS) represented a third approach and was independent from the NIST 
methodologies.
Figure 1 shows a comparison of results from the three methods for selected fatty acids. The 
certified or reference values derived from these results are also shown in the figure. In 
general, there was good agreement among the methods used, even for fatty acids present in 
SRM 1950 at low concentrations. Oleic acid, palmitic acid, and linoleic acid were the most 
abundant fatty acids measured in SRM 1950, and these results are consistent with U.S. 
population data from NHANES.59 Omega-3 fatty acids are of interest because of their 
potential cardioprotective effects,49 and several omega-3 fatty acids were measured in SRM 
1950, as shown in Table 3. SRM 1950 represents the first serum or plasma-based NIST SRM 
with values assigned for fatty acids.
Vitamins and Carotenoids
Numerous studies have attempted to discern the relationship between diet and the risk of 
disease. Nutrients such as carotenoids and vitamin D may reduce the risk of cancer or other 
diseases in certain populations.60,61 However, identifying individuals more likely to respond 
to dietary interventions remains an elusive goal.62 Metabolomics studies may provide 
answers to some of the seemingly contradictory results that have been reported in nutrition 
research.63
Vitamin A, vitamin E, and carotenoids were determined in SRM 1950 using a combination 
of LC-UV methods, as shown in Table 4. The NIST methods utilized two different types of 
chromatographic columns, and additional method details are provided in the Supporting 
Information. Whenever possible, the values in Table 4 represent a combination of the results 
obtained by NIST and CDC. In some cases, however, assigned values for the carotenoids 
were based solely upon measurements performed at CDC. Metabolites arising from two 
water-soluble vitamins (folate and vitamin B6) and one additional fat-soluble vitamin 
(vitamin D) were also measured in SRM 1950, and these results are included in Table 4. The 
certified and reference values for these analytes were based primarily upon ID-MS methods, 
but an LC-FL method was included for analysis of pyridoxal 5′-phosphate, a vitamin B6 
metabolite.
CONCLUSIONS
SRM 1950 Metabolites in Human Plasma represents the first reference material developed 
specifically to support measurement quality assurance in metabolomics research. This SRM 
will complement existing approaches including the use of internal standards and QC 
materials that are already being employed in metabolomics analyses. In addition, SRM 1950 
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is intended to facilitate the development and validation of new metabolomics technology. 
Sufficient material was acquired to ensure approximately 10 years of availability for this 
SRM, and stability of the material is routinely monitored. Work to characterize the 
metabolite profile of SRM 1950 is continuing, and additional values will be added as they 
become available.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Comparison of results (mg/g) for selected fatty acids in SRM 1950. For the individual 
methods, the error bars represent one standard deviation. For the certified and reference 
values, the error bars represent the expanded uncertainty, U.
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Table 1
Concentrations of Clinical Markers in SRM 1950a
analyte mass concentration (mg/dL) molar concentration (mmol/L) method
bilirubin 0.344 ± 0.023 spectrophotometry
cholesterol 151.4 ± 3.3    3.917 ± 0.085 ID GC-MS
creatinine 0.6789 ± 0.0108 0.0600 ± 0.0009 ID LC-MS
glucose 82.16 ± 1.00  4.560 ± 0.056 ID GC-MS
total glycerides 99.0 ± 2.1  1.12 ± 0.02 ID GC-MS
calcium 1.936 ± 0.024 ID ICP-MS
magnesium 0.696 ± 0.004 ID ICP-MS
potassium 3.665 ± 0.025 ID ICP-MS
sodium 141.76 ± 0.31    gravimetry
analyte mass concentration (mg/L) molar concentration (μmol/L) method
homocysteine 1.150 ± 0.026 8.50 ± 0.20 ID GC-MS
analyte mass fraction (ng/g) mass concentration (ng/mL) method
cortisol 82.2 ± 1.7  83.9 ± 1.7  ID LC-MS/MS
progesterone 1.452 ± 0.037 1.482 ± 0.038 ID LC-MS/MS
testosterone 2.169 ± 0.046 2.214 ± 0.047 ID LC-MS/MS
a
Certified values (bold font) and reference values (normal font) are provided with their associated uncertainties.
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Table 2
Concentrations of Amino Acids in SRM 1950 Metabolites in Human Plasmaa
amino acid mass fraction (mg/kg) molar concentration (μmol/L)
alanine 26.2 ± 2.2  300 ± 26
arginine 13.89 ± 0.40  81.4 ± 2.3
cysteine 5.26 ± 0.81 44.3 ± 6.9
cystine 1.83 ± 0.08   7.8 ± 0.4
glutamic acid 9.7 ± 2.5   67 ± 18
glycine 18.0 ± 1.2  245 ± 16
histidine 11.04 ± 0.55  72.6 ± 3.6
isoleucine 7.13 ± 0.42 55.5 ± 3.4
leucine 12.90 ± 0.82  100.4 ± 6.3  
lysine 20.0 ± 1.9  140 ± 14
methionine 3.26 ± 0.26 22.3 ± 1.8
ornithine 6.7 ± 0.4 52.1 ± 2.8
phenylalanine 8.2 ± 1.1 51 ± 7
proline 19.9 ± 1.1  177 ± 9  
serine 9.87 ± 0.44 95.9 ± 4.3
threonine 13.94 ± 0.70  119.5 ± 6.1  
tyrosine 10.17 ± 0.53  57.3 ± 3.0
valine 20.9 ± 1.2  182.2 ± 10.4
a
Certified values (bold font) and reference values (normal font) are provided with their associated uncertainties.
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Table 3
Concentrations of Fatty Acids in SRM 1950a
lipid name common name mass fraction (μg/g) molar concentration (μmol/L)
C12:0 lauric acid   1.86 ± 0.11   9.47 ± 0.57
C16:0 palmitic acid 594 ± 19 2364 ± 77  
C 16:1 n-7 palmitoleic acid 53.5 ± 6.4 215 ± 26
C18:0 stearic acid 179 ± 12 644 ± 41
C18:3 n-3 α-linolenic acid 14.9 ± 1.0 54.6 ± 3.6
C18:1 n-9 oleic acid 447 ± 43 1614 ± 154
C18:2 n-6 linoleic acid 780 ± 39 2838 ± 143
C22:0 behenic acid 15.9 ± 1.5 47.8 ± 4.6
C14:0 myristic acid 17.9 ± 3.8   80.1 ± 17.0
C14:1 myristoleic acid   1.57 ± 0.03   7.1 ± 0.1
C15:0 pentadecanoic acid   1.08 ± 0.01   4.56 ± 0.04
C17:0 margaric acid   4.7 ± 0.2 17.6 ± 0.7
C18:3 n-6 γ-linolenic acid 10.9 ± 2.3 39.9 ± 8.5
C18:1 n-7 vaccenic acid 37.7 ± 0.9 136 ± 3  
C20:0 arachidic acid   5.5 ± 0.2 18.0 ± 0.5
C20:1 gondolic acid   3.5 ± 0.1 11.5 ± 0.5
C20:2 (Z,Z)-11,14-eicosadienoic acid   5.7 ± 0.2 18.8 ± 0.6
C20:3 n-6 homo-γ-linolenic acid 41.8 ± 1.1 139 ± 4  
C20:4 n-6 arachidonic acid 293 ± 54   984 ± 180
C20:5 n-3 EPA 11.4 ± 0.1 38.6 ± 0.5
C22:1 erucic acid   1.1 ± 0.4   3.4 ± 1.3
C22:4 n-6 (Z,Z,Z,Z)-7,10,13,16-docosatetraenoic acid   8.3 ± 0.2 25.5 ± 0.6
C22:5 n-3 DPA 12.5 ± 0.2 38.5 ± 0.7
C22:5 n-6 (Z,Z,Z,Z,Z)-4,7,10,13,16-docosapentaenoic acid   6.3 ± 0.1 19.5 ± 0.4
C22:6 n-3 DHA 37.9 ± 6.8 118 ± 21
C24:0 lignoceric acid 16.8 ± 0.9 46.6 ± 2.6
C24:1 nervonic acid 25.6 ± 1.2 71.3 ± 3.2
a
Certified values are presented in bold.
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Table 4
Concentrations of Vitamins and Carotenoids in SRM 1950a
analyte mass fraction (mg/kg) mass concentration (μg/mL) method(s)
retinol 0.396 ± 0.034 0.404 ± 0.035 LC-UV
retinyl palmitate 0.0067 ± 0.0004 0.0069 ± 0.0004 LC-UV
retinyl stearate 0.0022 ± 0.0002 0.0023 ± 0.0002 LC-UV
α-tocopherol 8.01 ± 0.22 8.18 ± 0.22 LC-UV
γ- + β-tocopherol 1.67 ± 0.16 1.71 ± 0.17 LC-UV
trans-lycopene 0.14 ± 0.01 0.14 ± 0.01 LC-UV
total lycopene 0.32 ± 0.02 0.33 ± 0.02 LC-UV
lutein 0.067 ± 0.022 0.069 ± 0.023 LC-UV
zeaxanthin 0.021 ± 0.005 0.022 ± 0.005 LC-UV
β-cryptoxanthin 0.038 ± 0.003 0.039 ± 0.003 LC-UV
total α-carotene 0.025 ± 0.005 0.026 ± 0.005 LC-UV
total β-carotene 0.077 ± 0.004 0.079 ± 0.004 LC-UV
trans-β-carotene 0.071 ± 0.005 0.072 ± 0.005 LC-UV
cis-β-carotene 0.0040 ± 0.0003 0.0041 ± 0.0003 LC-UV
analyte mass fraction (ng/g) mass concentration (ng/mL) method(s)
25-hydroxyvitamin D2 0.51 ± 0.17 0.52 ± 0.17 ID LC-MS, ID LC-MS/MS
25-hydroxyvitamin D3 24.27 ± 0.75  24.78 ± 0.77  ID LC-MS, ID LC-MS/MS
5-methyltetrahydrofolate 12.11 ± 0.31  12.36 ± 0.32  ID LC-MS/MS
folic acid 1.48 ± 0.44 1.51 ± 0.45 ID LC-MS/MS
pyridoxal 5′-phosphate 8.02 ± 0.45 8.19 ± 0.46 ID LC-MS/MS, LC-FL
a
Certified values are given in bold.
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